Equities

National Graphite Corp

NGRC:PKL

National Graphite Corp

Actions
Basic MaterialsIndustrial Metals and Mining
  • Price (USD)0.056
  • Today's Change0.008 / 17.87%
  • Shares traded135.00
  • 1 Year change+13.11%
  • Beta-2.0217
Data delayed at least 15 minutes, as of Oct 09 2024 20:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

National Graphite Corp., formerly Lucky Boy Silver Corporation, is a biopharmaceutical risk/cost-sharing company. The Company is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The Company operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.97m
  • Incorporated2011
  • Employees0.00
  • Location
    National Graphite CorpImmermannstr. 65ADUESSELDORF 40210GermanyDEU
  • Phone+49 211699380
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Plus Therapeutics Inc (USA)5.51m-13.23m8.02m20.00------1.46-3.05-3.051.19-1.340.4336----275,450.00-104.14-59.18---133.04-----240.15-470.45---4.17----2,093.30-5.8934.32--3.77--
Mustang Bio Inc0.00-32.06m8.04m80.00---------2.91-2.910.00-0.23840.00----0.00-170.53-70.02-727.24-79.98--------------------33.44---60.75--
Vitro Biopharma Inc1.85m-9.72m8.05m10.00------4.35-2.18-2.180.4159-1.640.23241.5824.96185,140.00-122.00---1,146.77--82.88---524.87--0.169-5.375.49---46.45--31.01------
Calidi Biotherapeutics Inc0.00-24.92m8.16m41.00---------5.41-5.410.00-1.820.00----0.00-279.89-----------------27.58-----100.00---14.90------
Nascent Biotech Inc0.00-1.92m8.32m-----------0.012-0.0120.00-0.0030.00-------1,256.81-708.50-----------589.83------------25.47------
Check Cap Ltd0.00-17.57m8.38m85.00--0.3539-----3.00-3.000.004.050.00-------49.87-54.23-53.46-60.24------------0.00------8.06---2.46--
Traws Pharma Inc226.00k-137.05m8.57m16.00------37.91-138.17-138.170.25576.030.0092--12.9114,125.00-557.63-63.43-896.39-85.72-----60,641.15-3,257.92----0.00--0.00-28.720.0844------
Enzon Pharmaceuticals Inc26.00k314.00k8.64m0.0027.522.84--332.250.00420.00420.00040.62770.0006------3.39-0.86543.42-0.8851----6,111.54-159.43----0.00---100.00--106.71-55.86----
National Graphite Corp0.00-1.97m8.64m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
Cell MedX Corp0.00-142.49k8.92m0.00---------0.0021-0.00210.00-0.00280.00-------190.76-703.78------84.03---2,996.54---4.35-----100.00--71.22------
Galecto Inc0.00-25.43m8.94m13.00--0.3293-----23.45-23.450.0021.740.00----0.00-59.06-48.46-75.34-52.36------------0.00------37.77------
Carmell Corp12.32k-15.97m8.97m9.00------727.79-1.53-1.440.0006-0.0656------1,368.89--------58.73---129,263.60--0.6901-----------75.70------
Viracta Therapeutics Inc0.00-45.34m9.13m40.00---------1.16-1.160.000.06780.00----0.00-83.82-86.35-140.98-106.38-------11,853.94---59.780.8753-------3.78------
Soligenix Inc494.62k-7.04m9.14m13.00--1.79--18.49-9.58-9.580.61522.250.0418--8.7038,047.69-59.45-75.40-121.64-154.328.7522.83-1,423.81-620.02----0.4421---11.54-30.6755.50------
GlycoMimetics Inc10.00k-39.11m9.25m35.00--0.4612--925.34-0.6071-0.60710.00020.31110.0002--0.0685285.71-90.71-43.60-103.87-47.82-----391,132.40-2,243.52----0.00---86.67--20.97---29.82--
Transcode Therapeutics Inc0.00-17.91m9.34m10.00--2.97-----75.48-75.480.000.1820.00----0.00-334.48-133.14-973.00-181.26-----------90.110.00-------5.59------
Data as of Oct 09 2024. Currency figures normalised to National Graphite Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.